The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Mechanisms of Action of Mycophenolate Mofetil in Preventing Acute and Chronic Allograft Rejection
Abstract
Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), an inhibitor of inosine-5'-monophosphate dehydrogenase, has several immunosuppressant actions. MPA depletes guanosine and deoxyguanosine nucleotides preferentially in T and B lymphocytes, inhibiting proliferation and suppressing cell-mediated immune responses and antibody formation, major factors in acute and chronic rejection. MPA also can induce T-lymphocyte apoptosis. MPA suppresses dendritic cell maturation and can induce human monocyte-macrophage cell line differentiation, decreasing the expression of interleukin (IL)-1 and enhancing expression of the IL-1 receptor antagonist. In addition, MPA inhibits adhesion molecule glycosylation and expression and lymphocyte and monocyte recruitment. Activated macrophages produce nitric oxide (NO) and superoxide, which combine to generate tissue-damaging peroxynitrite. MPA depletes tetrahydrobiopterin and decreases NO production by inducible NO synthase without affecting constitutive NO synthase activity. By these mechanisms, MMF exerts anti-inflammatory activity, which could attenuate both acute and chronic rejection. Unlike calcineurin inhibitors, MMF is nonnephrotoxic and does not induce transforming growth factor-beta production, which is fibrogenic. MMF inhibits arterial smooth muscle cell proliferation, a contributor to graft proliferative arteriopathy, and does not increase blood pressure, cholesterol, or triglyceride levels. By decreasing high-density lipoprotein oxidation and macrophage recruitment, MMF also may delay onset/progression of graft atherosclerosis. Thus, MMF may prevent chronic rejection by several mechanisms. MMF activity is synergistic with that of other agents such as valganciclovir for treating cytomegalovirus infection. MMF also has synergistic activity with angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists in the treatment of some nephropathies in experimental animals. This combination may prevent progression toward end-stage renal disease in humans with chronic allograft, lupus, and diabetic nephropathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ADENOSINE-DEAMINASE DEFICIENCY IN TWO PATIENTS WITH SEVERELY IMPAIRED CELLULAR IMMUNITY
Giblett, E., Anderson, J., Cohen, F., Pollara, B., & Meuwissen, H. (1972) · The Lancet · doi:10.1016/s0140-6736(72)92345-8 · Cited by 1,636
Biological effects of cyclosporin A: A new antilymphocytic agent
Borel, J. F., Feurer, C., Gubler, H. U., & Stähelin, H. (1976) · Agents and Actions · doi:10.1007/bf01973261 · Cited by 1,509
Mycophenolate mofetil and its mechanisms of action
Allison, A. C., & Eugui, E. M. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00188-0 · Cited by 1,433
Self-citationHench, P. S., Kendall, E. C., Slocumb, C. H., & Polley, H. F. (1949) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00526-3 · Cited by 1,179
Calne, R. Y., Rolles, K., Thiru, S., Mcmaster, P., Craddock, G. N., Aziz, S., White, D. J. G., Evans, D. B., Dunn, D. C., Henderson, R. G., et al. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92440-1 · Cited by 1,083
Sequential Therapies for Proliferative Lupus Nephritis
Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O'Nan, P., & Roth, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031855 · Cited by 818
Enzymatic function of nitric oxide synthases
Andrew, P. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00115-7 · Cited by 753
Zheng, L., Nukuna, B., Brennan, M.-L., Sun, M., Goormastic, M., Settle, M., Schmitt, D., Fu, X., Thomson, L., Fox, P. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421109 · Cited by 737
Effects of the new anti-lymphocytic peptide cyclosporin A in animals.
Borel, J. F., Feurer, C., Magnée, C., & Stähelin, H. (1977) · PubMed Central · Cited by 707
Chan, O. T. M., Hannum, L. G., Haberman, A. M., Madaio, M. P., & Shlomchik, M. J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.10.1639 · Cited by 698
Cited by
Ribosomal proteins: functions beyond the ribosome
Zhou, X., Liao, W.-J., Liao, J.-M., Liao, P., & Lu, H. (2015) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjv014 · Cited by 743
M1/M2 macrophages and their overlaps – myth or reality?
Strizova, Z., Benesova, I., Bartolini, R., Novysedlak, R., Cecrdlova, E., Foley, L. K., & Striz, I. (2023) · Clinical Science · doi:10.1042/cs20220531 · Cited by 612
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
Roberts, M. B., & Fishman, J. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1189 · Cited by 277
Liver transplantation immunology: immunosuppression, rejection, and immunomodulation
Montano-Loza, A. J., Rodríguez-Perálvarez, M. L., Pageaux, G.-P., Sanchez-Fueyo, A., & Feng, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.030 · Cited by 208
Metadata
- Authors
- Allison, A. C., & Eugui, E. M.
- Venue
- Transplantation
- Published
- 2005-10
- Volume
- 80
- Issue
- Supplement
- Pages
- S181-S190
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1994453026
- Cited by
- 357
- References
- 53
- FWCI
- 21.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of Action of Mycophenolate Mofetil in Preventing Acute and Chronic Allograft Rejection. https://app.cochat.ai/papers/10.1097/01.tp.0000186390.10150.66
- The paper
- Allison, A. C., & Eugui, E. M. (2005). Mechanisms of Action of Mycophenolate Mofetil in Preventing Acute and Chronic Allograft Rejection. Transplantation. https://doi.org/10.1097/01.tp.0000186390.10150.66
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.